| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 测试业务(WuXi Testing)(元) | 2,688,647,220.66 | 5,670,738,410.03 | 3,018,355,999.39 | 6,539,666,743.74 | 3,091,000,383.52 |
| 国内新药研发服务部(WuXi DDSU)(元) | - | - | 257,177,952.01 | 726,452,550.24 | 341,986,707.21 |
| 化学业务(WuXi Chemistry)(元) | 16,301,370,405.46 | 29,052,409,079.42 | 12,209,866,826.82 | 29,171,488,182.59 | 13,467,202,622.69 |
| 生物学业务(WuXi Biology)(元) | 1,251,604,868.49 | 2,543,926,320.99 | 1,168,909,867.67 | 2,552,553,999.20 | 1,232,635,388.49 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(元) | - | - | 574,952,553.89 | 1,309,596,734.35 | 713,626,909.44 |
| 终止经营业务(元) | - | 1,323,649,163.45 | - | - | - |
| 其他业务(元) | 163,480,378.33 | 650,708,385.99 | - | - | - |
| 营业成本(元) | |||||
| 测试业务(WuXi Testing)(元) | 2,024,256,847.97 | 3,814,644,625.35 | 1,959,376,484.09 | 4,093,976,831.49 | 1,964,556,775.56 |
| 国内新药研发服务部(WuXi DDSU)(元) | - | - | 106,846,974.62 | 466,931,958.98 | 245,381,960.27 |
| 化学业务(WuXi Chemistry)(元) | 8,302,923,339.92 | 15,574,099,540.41 | 6,889,155,768.40 | 16,184,176,275.97 | 7,488,797,778.70 |
| 生物学业务(WuXi Biology)(元) | 813,008,608.78 | 1,584,978,592.32 | 747,196,887.66 | 1,522,571,429.70 | 747,414,521.74 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(元) | - | - | 745,749,242.37 | 1,441,084,850.72 | 763,892,666.82 |
| 终止经营业务(元) | - | 1,536,931,193.83 | - | - | - |
| 其他业务(元) | 69,866,314.78 | 453,861,508.71 | - | - | - |
| 毛利(元) | |||||
| 测试业务(WuXi Testing)(元) | 664,390,372.69 | 1,856,093,784.68 | 1,058,979,515.30 | 2,445,689,912.25 | 1,126,443,607.96 |
| 国内新药研发服务部(WuXi DDSU)(元) | - | - | 150,330,977.39 | 259,520,591.26 | 96,604,746.94 |
| 化学业务(WuXi Chemistry)(元) | 7,998,447,065.54 | 13,478,309,539.01 | 5,320,711,058.42 | 12,987,311,906.62 | 5,978,404,843.99 |
| 生物学业务(WuXi Biology)(元) | 438,596,259.71 | 958,947,728.67 | 421,712,980.01 | 1,029,982,569.50 | 485,220,866.75 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(元) | - | - | -170,796,688.48 | -131,488,116.37 | -50,265,757.38 |
| 终止经营业务(元) | - | -213,282,030.38 | - | - | - |
| 其他业务(元) | 93,614,063.55 | 196,846,877.28 | - | - | - |
| 毛利率(%) | |||||
| 测试业务(WuXi Testing)(%) | 24.71 | 32.73 | 35.08 | 37.40 | 36.44 |
| 国内新药研发服务部(WuXi DDSU)(%) | - | - | 58.45 | 35.72 | 28.25 |
| 化学业务(WuXi Chemistry)(%) | 49.07 | 46.39 | 43.58 | 44.52 | 44.39 |
| 生物学业务(WuXi Biology)(%) | 35.04 | 37.70 | 36.08 | 40.35 | 39.36 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(%) | - | - | -29.71 | -10.04 | -7.04 |
| 终止经营业务(%) | - | -16.11 | - | - | - |
| 其他业务(%) | 57.26 | 30.25 | - | - | - |
| 收入构成(%) | |||||
| 测试业务(WuXi Testing)(%) | 13.18 | 14.45 | 17.52 | 16.23 | 16.40 |
| 国内新药研发服务部(WuXi DDSU)(%) | - | - | 1.49 | 1.80 | 1.81 |
| 化学业务(WuXi Chemistry)(%) | 79.89 | 74.04 | 70.87 | 72.39 | 71.46 |
| 生物学业务(WuXi Biology)(%) | 6.13 | 6.48 | 6.78 | 6.33 | 6.54 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(%) | - | - | 3.34 | 3.25 | 3.79 |
| 终止经营业务(%) | - | 3.37 | - | - | - |
| 其他业务(%) | 0.80 | 1.66 | - | - | - |
| 毛利构成(%) | |||||
| 测试业务(WuXi Testing)(%) | 7.23 | 11.40 | 15.62 | 14.74 | 14.75 |
| 国内新药研发服务部(WuXi DDSU)(%) | - | - | 2.22 | 1.56 | 1.27 |
| 化学业务(WuXi Chemistry)(%) | 86.99 | 82.81 | 78.47 | 78.28 | 78.29 |
| 生物学业务(WuXi Biology)(%) | 4.77 | 5.89 | 6.22 | 6.21 | 6.35 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(%) | - | - | -2.52 | -0.79 | -0.66 |
| 终止经营业务(%) | - | -1.31 | - | - | - |
| 其他业务(%) | 1.02 | 1.21 | - | - | - |